BCTX BriaCell Therapeutics
- 1.420
- +0.060+4.41%
- 1.450
- +0.030+2.11%
BriaCell Therapeutics News
10-Q: Quarterly report
Express News | HC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $18 Price Target
BriaCell Presents Clinical Efficacy Data at ASCO 2024
BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literatureBria-IMT PFS compares favorably to PFS of most recent treatment in 48% of Antibody-Dru
Express News | Briacell Initiates Patient Enrollment in First-in-Human Study of Bria-Ots™ in Advanced Metastatic Breast Cancer
BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS in Advanced Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, May 30, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnol
Express News | BriaCell Therapeutics Announces Clinical Supply Agreement With BeiGene To Evaluate Safety And Efficacy Of Bria-OTS, BriaCell's Next Generation Immunotherapy
Express News | Briacell Announces Clinical Supply Agreement With Beigene for Bria-Ots™ First in Human Study
BriaCell Announces Clinical Supply Agreement With BeiGene for Bria-OTS First in Human Study
Study to evaluate the effects of Bria-OTS in combination with anti-PD-1 antibody tislelizumab, in advanced, late stage, heavily pretreated metastatic breast cancer. PHILADELPHIA and VANCOUVER, British
BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024
83% intracranial objective response rate (iORR) with Bria-IMT in heavily pretreated advanced breast cancer patients with CNS metastasesMedian progression free survival (PFS) of 4.1 months in ADC resistant
BriaCell Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/24/2024 1185.44% HC Wainwright & Co. → $18 Reiterates Buy → Buy 12/28/2023 1185.44% HC Wainwright & Co.
This BriaCell Therapeutics Insider Increased Their Holding By 55% Last Year
H.C. Wainwright Maintains BriaCell Therapeutics(BCTX.US) With Buy Rating, Maintains Target Price $18
H.C. Wainwright analyst Emily Bodnar maintains $BriaCell Therapeutics(BCTX.US)$ with a buy rating, and maintains the target price at $18.According to TipRanks data, the analyst has a success rate of 3
Briacell Therapeutics Insider Bought Shares Worth $2,000,001, According to a Recent SEC Filing
Marc Lustig, 10% Owner, Director, on May 14, 2024, executed a purchase for 902,935 shares in Briacell Therapeutics (BCTX) for $2,000,001. Following the Form 4 filing with the SEC, Lustig has control o
BriaCell Therapeutics Secures $5M in Funding
Express News | Briacell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
PHILADELPHIA and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnol
Express News | BriaCell Therapeutics Shares Are Trading Lower After the Company Announced the Pricing of a $5 Million Registered Direct Offering of 2,402,935 Shares and Warrants at a Combined Purchase Price of $2 per Share
BriaCell Therapeutics Prices $5 Million Offering; Shares Tumble
BriaCell Therapeutics (BCTX) shares were slumping about 10% in recent US trading on Wednesday after the immunotherapy company said it priced a private placement of slightly more than 2.4 million of it
BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering
BriaCell Therapeutics to Present Bria-IMT Phase 2 Findings at American Society of Clinical Oncology Annual Meeting
BriaCell Therapeutics (BCT.TO), which is developing immunotherapies to treat cancer, said it will make a presentation on the clinical data of the randomized Phase 2 study evaluating Bria-IMT in patien
Analysis
Price Target
No Data
